drug

firmonertinib

1 story · latest Aug 12, 2026

Status: Investigational
Code: AST2818
Trials: 1 registered trial in coverage

Relationships

Developed by ArriVent BioPharma, Inc.

Timeline

ArriVent reports Q2 2026 results, licenses ARR-002 to Allist in Greater China

Aug 12Clinical readoutARR-002 ArriVent BioPharma, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.